 Scott Auerbach
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 34 | 2023 | 671 | 6.980 |
Why?
| | Heart-Assist Devices | 16 | 2023 | 486 | 3.450 |
Why?
| | Heart Failure | 23 | 2023 | 1963 | 2.900 |
Why?
| | Graft Rejection | 11 | 2022 | 533 | 2.010 |
Why?
| | Graft Survival | 9 | 2023 | 481 | 1.440 |
Why?
| | Heart Diseases | 3 | 2023 | 332 | 1.120 |
Why?
| | Cardiomyopathies | 9 | 2023 | 303 | 1.060 |
Why?
| | Muscular Dystrophy, Duchenne | 4 | 2022 | 81 | 1.030 |
Why?
| | Child | 47 | 2023 | 18539 | 1.020 |
Why?
| | Steroids | 2 | 2015 | 147 | 0.910 |
Why?
| | Myocarditis | 2 | 2023 | 95 | 0.860 |
Why?
| | Heart Defects, Congenital | 7 | 2023 | 660 | 0.770 |
Why?
| | Kidney Transplantation | 2 | 2023 | 559 | 0.730 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 491 | 0.630 |
Why?
| | Child, Preschool | 20 | 2023 | 9165 | 0.620 |
Why?
| | Immunosuppressive Agents | 4 | 2023 | 666 | 0.600 |
Why?
| | Registries | 13 | 2023 | 1772 | 0.600 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 613 | 0.580 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 243 | 0.560 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 70 | 0.560 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 366 | 0.560 |
Why?
| | Adolescent | 29 | 2023 | 17940 | 0.550 |
Why?
| | Disease Management | 1 | 2020 | 563 | 0.550 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 352 | 0.530 |
Why?
| | Retrospective Studies | 20 | 2023 | 12616 | 0.500 |
Why?
| | Cardiology | 1 | 2017 | 260 | 0.500 |
Why?
| | Stroke | 1 | 2023 | 1016 | 0.490 |
Why?
| | Humans | 60 | 2023 | 115879 | 0.490 |
Why?
| | Treatment Outcome | 15 | 2023 | 9164 | 0.480 |
Why?
| | Myocardium | 3 | 2022 | 929 | 0.450 |
Why?
| | Infant | 16 | 2022 | 7992 | 0.420 |
Why?
| | Young Adult | 12 | 2023 | 10510 | 0.420 |
Why?
| | Male | 33 | 2023 | 56117 | 0.410 |
Why?
| | Echocardiography | 3 | 2022 | 565 | 0.380 |
Why?
| | Delivery of Health Care | 1 | 2017 | 847 | 0.370 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 99 | 0.350 |
Why?
| | Organ Transplantation | 2 | 2022 | 161 | 0.340 |
Why?
| | Female | 28 | 2023 | 60082 | 0.340 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 53 | 0.330 |
Why?
| | Risk Factors | 12 | 2022 | 8715 | 0.320 |
Why?
| | Postoperative Complications | 4 | 2021 | 2164 | 0.280 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 447 | 0.280 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 469 | 0.270 |
Why?
| | Risk Assessment | 1 | 2015 | 2992 | 0.270 |
Why?
| | Interleukin-6 | 1 | 2009 | 677 | 0.250 |
Why?
| | Stroke Volume | 4 | 2022 | 510 | 0.250 |
Why?
| | Infant, Newborn | 9 | 2020 | 5084 | 0.240 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1088 | 0.230 |
Why?
| | Transplant Recipients | 2 | 2022 | 143 | 0.230 |
Why?
| | Incidence | 3 | 2020 | 2336 | 0.230 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1443 | 0.220 |
Why?
| | Vasoplegia | 1 | 2022 | 2 | 0.220 |
Why?
| | Heart Injuries | 1 | 2023 | 37 | 0.210 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 36 | 0.210 |
Why?
| | DNA | 1 | 2009 | 1357 | 0.210 |
Why?
| | American Heart Association | 2 | 2021 | 266 | 0.210 |
Why?
| | Clinical Protocols | 1 | 2022 | 234 | 0.190 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1182 | 0.190 |
Why?
| | Coronary Vessels | 2 | 2021 | 230 | 0.180 |
Why?
| | Age Factors | 4 | 2021 | 2911 | 0.180 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 605 | 0.180 |
Why?
| | United States | 9 | 2022 | 12322 | 0.180 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.180 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2365 | 0.170 |
Why?
| | Stents | 1 | 2023 | 475 | 0.170 |
Why?
| | Spironolactone | 1 | 2019 | 33 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 816 | 0.170 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4444 | 0.170 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 43 | 0.170 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 132 | 0.170 |
Why?
| | Consensus | 1 | 2021 | 531 | 0.160 |
Why?
| | Ultrasonography | 2 | 2020 | 669 | 0.160 |
Why?
| | Fontan Procedure | 1 | 2021 | 156 | 0.160 |
Why?
| | Global Health | 1 | 2020 | 290 | 0.150 |
Why?
| | Coronary Angiography | 1 | 2020 | 315 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 488 | 0.150 |
Why?
| | Cohort Studies | 4 | 2021 | 4960 | 0.150 |
Why?
| | Adult | 9 | 2023 | 30822 | 0.150 |
Why?
| | Patient Selection | 1 | 2021 | 655 | 0.150 |
Why?
| | Arsenic | 1 | 2017 | 37 | 0.150 |
Why?
| | Databases, Factual | 3 | 2019 | 1137 | 0.150 |
Why?
| | Isoantibodies | 1 | 2017 | 52 | 0.150 |
Why?
| | Uniparental Disomy | 1 | 2017 | 7 | 0.140 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 18 | 0.140 |
Why?
| | Tooth Extraction | 1 | 2017 | 20 | 0.140 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 29 | 0.140 |
Why?
| | Epigenomics | 1 | 2017 | 106 | 0.140 |
Why?
| | Donor Selection | 1 | 2017 | 73 | 0.140 |
Why?
| | Muscular Diseases | 1 | 2017 | 104 | 0.140 |
Why?
| | Waiting Lists | 3 | 2023 | 223 | 0.140 |
Why?
| | Anesthesia, General | 1 | 2017 | 44 | 0.140 |
Why?
| | Kidney | 1 | 2023 | 1210 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2019 | 336 | 0.140 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 119 | 0.140 |
Why?
| | Biomarkers | 5 | 2017 | 3474 | 0.140 |
Why?
| | Trisomy | 1 | 2017 | 68 | 0.140 |
Why?
| | HLA Antigens | 1 | 2017 | 224 | 0.140 |
Why?
| | Benchmarking | 1 | 2017 | 163 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1359 | 0.130 |
Why?
| | Perioperative Care | 1 | 2017 | 127 | 0.130 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 90 | 0.130 |
Why?
| | Models, Chemical | 1 | 2017 | 257 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 249 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2020 | 552 | 0.130 |
Why?
| | Equipment Failure | 1 | 2015 | 109 | 0.120 |
Why?
| | Crohn Disease | 1 | 2017 | 197 | 0.120 |
Why?
| | Proteome | 1 | 2017 | 346 | 0.110 |
Why?
| | Propensity Score | 1 | 2015 | 225 | 0.110 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 478 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 958 | 0.110 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.110 |
Why?
| | Hemodynamics | 2 | 2018 | 969 | 0.110 |
Why?
| | Disease Progression | 1 | 2020 | 2423 | 0.110 |
Why?
| | Anxiety | 1 | 2019 | 855 | 0.110 |
Why?
| | Time Factors | 4 | 2022 | 6182 | 0.110 |
Why?
| | Dexmedetomidine | 1 | 2013 | 45 | 0.110 |
Why?
| | Hospitalization | 1 | 2022 | 1766 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 724 | 0.110 |
Why?
| | Mental Disorders | 1 | 2020 | 903 | 0.100 |
Why?
| | Heart | 2 | 2022 | 612 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 682 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2017 | 487 | 0.100 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 292 | 0.100 |
Why?
| | Recovery of Function | 1 | 2015 | 577 | 0.090 |
Why?
| | Prognosis | 3 | 2018 | 3344 | 0.090 |
Why?
| | Pediatrics | 1 | 2018 | 986 | 0.090 |
Why?
| | Antibody Formation | 2 | 2022 | 274 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4675 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 1814 | 0.090 |
Why?
| | Carbazoles | 1 | 2010 | 80 | 0.090 |
Why?
| | Propanolamines | 1 | 2010 | 94 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2017 | 1217 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 249 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 390 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 501 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 610 | 0.080 |
Why?
| | Survival Analysis | 1 | 2011 | 1218 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 293 | 0.080 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 397 | 0.080 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 16 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 754 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 72 | 0.070 |
Why?
| | Genotype | 2 | 2009 | 1830 | 0.070 |
Why?
| | Aged | 2 | 2023 | 19296 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1001 | 0.070 |
Why?
| | Hemofiltration | 1 | 2006 | 31 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 1725 | 0.070 |
Why?
| | Biopsy | 1 | 2009 | 1056 | 0.060 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 89 | 0.060 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 105 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 633 | 0.060 |
Why?
| | Vaccination | 2 | 2023 | 1210 | 0.060 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 37 | 0.060 |
Why?
| | Everolimus | 1 | 2023 | 63 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1551 | 0.050 |
Why?
| | Survival Rate | 2 | 2017 | 1650 | 0.050 |
Why?
| | Middle Aged | 2 | 2021 | 27085 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2023 | 81 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1752 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 143 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 124 | 0.050 |
Why?
| | Bias | 1 | 2022 | 181 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 33 | 0.050 |
Why?
| | Social Class | 1 | 2022 | 210 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2022 | 204 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4447 | 0.050 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 180 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2022 | 223 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 962 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 527 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 162 | 0.040 |
Why?
| | Prospective Studies | 3 | 2018 | 6279 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 166 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2019 | 195 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2019 | 316 | 0.040 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 2 | 0.040 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 6 | 0.040 |
Why?
| | Barth Syndrome | 1 | 2017 | 9 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 175 | 0.040 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 5 | 0.040 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 12 | 0.040 |
Why?
| | Brazil | 1 | 2017 | 105 | 0.040 |
Why?
| | Infliximab | 1 | 2017 | 94 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 43 | 0.040 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 60 | 0.040 |
Why?
| | Death | 1 | 2017 | 109 | 0.040 |
Why?
| | Sample Size | 1 | 2017 | 119 | 0.040 |
Why?
| | United Kingdom | 1 | 2017 | 230 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 63 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 64 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 290 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 90 | 0.030 |
Why?
| | Canada | 1 | 2017 | 337 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 54 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1476 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 540 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1664 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 204 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 66 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 331 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 119 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1060 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2021 | 2581 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 319 | 0.030 |
Why?
| | Electrocardiography | 1 | 2017 | 560 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 452 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 917 | 0.030 |
Why?
| | Transcriptome | 1 | 2017 | 742 | 0.030 |
Why?
| | Quality of Life | 1 | 2022 | 2390 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2590 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 991 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 713 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 2807 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1871 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 90 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 103 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 503 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 514 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 506 | 0.020 |
Why?
| | Subclavian Vein | 1 | 2006 | 19 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 5555 | 0.020 |
Why?
| | Alleles | 1 | 2007 | 818 | 0.020 |
Why?
| | Base Sequence | 1 | 2007 | 2121 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 2859 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|